New Delhi, India & New York, United States, August 19, 2026
Zeon Lifesciences, an India-based nutraceutical manufacturer, has strengthened its readiness to serve the U.S. market through FDA facility registration, successful FDA clearance inspections, and global quality certifications. The company said the developments reinforce its ability to meet applicable requirements for supplying dietary supplement and other food products to the United States. Zeon has also secured NSF certification aligned with 21 CFR Part 111, the FDA’s current Good Manufacturing Practice requirements for dietary supplements. The regulatory and quality milestones form part of the company’s broader international expansion strategy and are intended to strengthen its position as a manufacturing and CDMO partner for global nutraceutical brands.
FDA Registration Supports U.S. Market Expansion
Zeon Lifesciences’ FDA-registered facility represents an important step in its strategy to support customers targeting the U.S. market. FDA food-facility registration applies to facilities involved in manufacturing, processing, packing, or holding food products, including dietary supplements, for the U.S. market. The company said its facility has also undergone clearance inspections by U.S. FDA officials under the Food Safety Modernization Act (FSMA), reinforcing its preparedness to operate within the applicable U.S. food-safety regulatory framework. While facility registration supports market readiness, individual products remain subject to applicable requirements involving ingredients, labeling, safety, imports, and market access. Zeon’s latest developments therefore represent a broader investment in the regulatory infrastructure needed to support international nutraceutical manufacturing. The company said its U.S.-focused readiness program is intended to help brands seeking experienced manufacturing partners in India while maintaining appropriate quality and documentation standards for regulated international markets.
NSF Certification Strengthens Quality Systems
Alongside its FDA registration and inspection milestones, Zeon has strengthened its quality credentials through NSF certification aligned with 21 CFR Part 111. The regulation establishes current Good Manufacturing Practice requirements for dietary supplement manufacturing, including controls related to production, quality systems, documentation, testing, and finished products. Zeon said it continues to invest in manufacturing systems, quality processes, documentation, testing, and regulatory capabilities to support consistent standards across its operations. The company is also strengthening U.S.-compliant packaging and labeling artwork, finished-product testing, documentation, and customer-support processes. These capabilities are increasingly important for nutraceutical manufacturers seeking to serve brands operating across multiple regulated markets. By combining manufacturing infrastructure with quality and regulatory systems, Zeon aims to provide customers with a more integrated pathway covering product development, formulation, manufacturing, testing, and scale-up.
Advertisement
CDMO Capabilities Support Global Brands
The latest regulatory milestones form part of Zeon’s wider strategy to expand its role as an international nutraceutical manufacturing and CDMO partner. The company expects opportunities to grow among U.S. and international brands seeking manufacturing partners capable of supporting products from development through commercial-scale production. Zeon’s export-oriented readiness program is complemented by investments in manufacturing infrastructure, innovation, quality management, and regulatory support. According to the company, its objective is to combine regulatory preparedness, manufacturing expertise, quality systems, and operational consistency to create a stronger foundation for long-term partnerships with global brands. The U.S. market represents a significant opportunity for Zeon, particularly as nutraceutical companies seek manufacturing partners capable of meeting evolving quality and regulatory expectations. The company’s FDA registration, inspection experience, and NSF certification provide additional credentials as it expands its international footprint. However, the developments relate primarily to nutraceutical and dietary supplement manufacturing rather than conventional pharmaceutical drug manufacturing. For cGxP.wire, the announcement is particularly relevant to the Food category because it connects U.S. regulatory readiness, cGMP requirements, quality assurance, and nutraceutical manufacturing capabilities.
Source: Zeon Lifesciences press relese
